Controlled Nucleation for a Monoclonal Antibody Formulation—A Case Study

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2015
Volume 2015 eBook
Issue 2

This study evaluates the impact of controlled nucleation on the ability to optimize a lyophilization cycle for a monoclonal antibody formulation.

 

This study evaluates the impact of controlled nucleation on the ability to optimize a lyophilization cycle for a monoclonal antibody formulation.

Download

Pharmaceutical Technology’s 2015 Bioprocessing and Sterile Manufacturing eBook


 

Articles in this issue
PTeBook0515_024-030_Container200.jpg
Sterilization Effects on Elastomers in Sterile Parenteral Drug Products
PTebook0515_Linde200.jpg
Controlled Nucleation for a Monoclonal Antibody Formulation—A Case Study
PTeBook0515_EMDConfarma200.jpg
Validating and Implementing a Rapid Sterility Testing Method
PTeBook0515_Vetter200.jpg
Disposable Technology versus Traditional Stainless Steel--When Time Means Money
PTeBook0515_Cleanroom200.jpg
Cleanroom and Facility Planning: Getting Beyond Cost Per Square Foot
PTeBook0515_Aging_Facilities200.jpg
Aging Facilities: Aseptic Manufacturing Faces the Future
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

Feliza Mirasol
December 17th 2024
Article

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Feliza Mirasol
December 11th 2024
Article

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

Gary Ritchie;Sharon Flank
December 10th 2024
Article

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.